CD53 and breast cancer: Although the precise function and physiological role of this gene is unknown, the fact that it is a cell surface antigen that is highly expressed in different carcinomas and expressed at relatively low levels (if at all) in many normal tissues has led to its evaluation as a candidate therapeutic target for radioimmunotherapy treatment, particularly for breast cancer[28].